{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:09:59Z","timestamp":1793138999729,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2019,4,1]]},"DOI":"10.1001\/jamapsychiatry.2018.3907","type":"journal-article","created":{"date-parts":[[2019,1,9]],"date-time":"2019-01-09T15:35:55Z","timestamp":1547048155000},"page":"382","source":"Crossref","is-referenced-by-count":61,"title":["Association of Hydroxylmethyl Glutaryl Coenzyme A Reductase Inhibitors, L-Type Calcium Channel Antagonists, and Biguanides With Rates of Psychiatric Hospitalization and Self-Harm in Individuals With Serious Mental Illness"],"prefix":"10.1001","volume":"76","author":[{"given":"Joseph F.","family":"Hayes","sequence":"first","affiliation":[{"name":"Division of Psychiatry, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Lundin","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Epidemiology of Psychiatric Conditions, Substance Use, and Social Environment, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Wicks","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Epidemiology of Psychiatric Conditions, Substance Use, and Social Environment, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glyn","family":"Lewis","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C. K.","family":"Wong","sequence":"additional","affiliation":[{"name":"Centre for Medicines Optimisation Research and Education, Research Department of Practice and Policy, School of Pharmacy, University College London, London, United Kingdom"},{"name":"Department of Pharmacology and Pharmacy, University of Hong Kong, Pokfulam, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P. J.","family":"Osborn","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Dalman","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, Epidemiology of Psychiatric Conditions, Substance Use, and Social Environment, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"yoi180099r2","article-title":"Clinical trials and therapeutic rationale for drug repurposing in schizophrenia","author":"Lago","journal-title":"ACS Chem Neurosci"},{"issue":"7","key":"yoi180099r3","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/(ISSN)1099-1557","article-title":"The new Swedish Prescribed Drug Register: opportunities for pharmacoepidemiological research and experience from the first six months [published correction appears in Pharmacoepidemiol Drug Saf. 2008;17(5):533].","volume":"16","author":"Wettermark","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"yoi180099r4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.psychres.2018.02.018","article-title":"Adjunctive therapy with statins in schizophrenia patients: a meta-analysis and implications.","volume":"262","author":"Shen","year":"2018","journal-title":"Psychiatry Res"},{"issue":"10","key":"yoi180099r5","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/mp.2016.86","article-title":"A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development.","volume":"21","author":"Cipriani","year":"2016","journal-title":"Mol Psychiatry"},{"issue":"8","key":"yoi180099r6","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1002\/ajmg.b.31122","article-title":"L-type calcium channels and psychiatric disorders: a brief review.","volume":"153B","author":"Casamassima","year":"2010","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"10","key":"yoi180099r7","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/ng.2742","article-title":"Genome-wide association analysis identifies 13 new risk loci for schizophrenia.","volume":"45","author":"Ripke","year":"2013","journal-title":"Nat Genet"},{"issue":"3-4","key":"yoi180099r8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00213-003-1582-z","article-title":"NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.","volume":"169","author":"Krystal","year":"2003","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"yoi180099r9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/bcp.2011.71.issue-3","article-title":"Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.","volume":"71","author":"Praharaj","year":"2011","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"yoi180099r10","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.2174\/1871527313666141130205514","article-title":"Metformin: repurposing opportunities for cognitive and mood dysfunction.","volume":"13","author":"Ying","year":"2014","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"yoi180099r11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/1471-2288-11-106","article-title":"A self-controlled case series to assess the effectiveness of beta blockers for heart failure in reducing hospitalisations in the elderly.","volume":"11","author":"Ramsay","year":"2011","journal-title":"BMC Med Res Methodol"},{"issue":"9","key":"yoi180099r12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S2215-0366(17)30253-5","article-title":"Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: a total population study of Sweden.","volume":"4","author":"Bauer-Staeb","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"yoi180099r13","doi-asserted-by":"publisher","first-page":"i1030","DOI":"10.1136\/bmj.i1030","article-title":"Refugee migration and risk of schizophrenia and other non-affective psychoses: cohort study of 1.3 million people in Sweden.","volume":"352","author":"Hollander","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"yoi180099r14","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/08039480500360906","article-title":"Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses.","volume":"59","author":"Ekholm","year":"2005","journal-title":"Nord J Psychiatry"},{"issue":"8","key":"yoi180099r15","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1176\/appi.ajp.2017.16050542","article-title":"Suicidal behavior during lithium and valproate treatment: a within-individual 8-year prospective study of 50 000 patients with bipolar disorder.","volume":"174","author":"Song","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"9","key":"yoi180099r16","doi-asserted-by":"publisher","first-page":"e1001875","DOI":"10.1371\/journal.pmed.1001875","article-title":"Selective serotonin reuptake inhibitors and violent crime: a cohort study.","volume":"12","author":"Molero","year":"2015","journal-title":"PLoS Med"},{"issue":"4","key":"yoi180099r18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s10753-009-9178-3","article-title":"Lipid and C-reactive protein levels, cardiovascular disease risk factors and simvastatin treatment in Brazilian individuals.","volume":"33","author":"Rosendo","year":"2010","journal-title":"Inflammation"},{"key":"yoi180099r19","first-page":"103","article-title":"Atorvastatin attenuates the production of IL-1\u00df, IL-6, and TNF-a in the hippocampus of an amyloid \u00df1-42\u2013induced rat model of Alzheimer\u2019s disease.","volume":"8","author":"Zhang","year":"2013","journal-title":"Clin Interv Aging"},{"issue":"2","key":"yoi180099r20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","article-title":"In vitro P-glycoprotein affinity for atypical and conventional antipsychotics.","volume":"71","author":"Boulton","year":"2002","journal-title":"Life Sci"},{"issue":"11","key":"yoi180099r21","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00702-011-0680-z","article-title":"The neuroprotective effect of two statins: simvastatin and pravastatin on a streptozotocin-induced model of Alzheimer\u2019s disease in rats.","volume":"118","author":"Tramontina","year":"2011","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"yoi180099r22","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.neuroscience.2008.04.026","article-title":"Chronic treatment with simvastatin upregulates muscarinic M1\/4 receptor binding in the rat brain.","volume":"154","author":"Wang","year":"2008","journal-title":"Neuroscience"},{"issue":"3","key":"yoi180099r23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.neulet.2006.09.009","article-title":"Effects of high dose of simvastatin on levels of dopamine and its reuptake in prefrontal cortex and striatum among SD rats.","volume":"408","author":"Wang","year":"2006","journal-title":"Neurosci Lett"},{"issue":"2","key":"yoi180099r24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins.","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"issue":"pt 5","key":"yoi180099r25","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1042\/BST0340903","article-title":"Role of voltage-gated L-type Ca2+ channel isoforms for brain function.","volume":"34","author":"Striessnig","year":"2006","journal-title":"Biochem Soc Trans"},{"key":"yoi180099r26","article-title":"S225: a systematic review and meta-analysis of pharmacological interventions for reduction or prevention of weight gain in schizophrenia.","author":"Agarwal","journal-title":"Schizophren Bull"},{"key":"yoi180099r27","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.pnpbp.2012.09.016","article-title":"Immune system and glucose metabolism interaction in schizophrenia: a chicken-egg dilemma.","volume":"48","author":"Steiner","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"8","key":"yoi180099r28","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1177\/0269881116645254","article-title":"BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.","volume":"30","author":"Cooper","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"2","key":"yoi180099r29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1001\/jamapsychiatry.2014.2133","article-title":"Cardiovascular risk prediction models for people with severe mental illness: results from the Prediction and Management of Cardiovascular Risk in People With Severe Mental Illnesses (PRIMROSE) research program.","volume":"72","author":"Osborn","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"yoi180099r30","doi-asserted-by":"publisher","first-page":"j2099","DOI":"10.1136\/bmj.j2099","article-title":"Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study.","volume":"357","author":"Hippisley-Cox","year":"2017","journal-title":"BMJ"},{"issue":"9","key":"yoi180099r31","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2174\/1381612820666141013134447","article-title":"Adverse effects of statins: myths and reality.","volume":"21","author":"\u0160imic","year":"2015","journal-title":"Curr Pharm Des"},{"issue":"1","key":"yoi180099r32","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.amjmed.2003.08.027","article-title":"Calcium channel blockers: an update.","volume":"116","author":"Eisenberg","year":"2004","journal-title":"Am J Med"},{"issue":"1","key":"yoi180099r33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/0003-4819-137-1-200207020-00009","article-title":"Metformin: an update.","volume":"137","author":"Kirpichnikov","year":"2002","journal-title":"Ann Intern Med"},{"issue":"11","key":"yoi180099r34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00127-002-0582-3","article-title":"Young cases of schizophrenia identified in a national inpatient register: are the diagnoses valid?","volume":"37","author":"Dalman","year":"2002","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"5","key":"yoi180099r35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/acp.2010.121.issue-5","article-title":"The Stockholm Non-Affective Psychoses Study (SNAPS): the importance of including out-patient data in incidence studies.","volume":"121","author":"J\u00f6rgensen","year":"2010","journal-title":"Acta Psychiatr Scand"},{"key":"yoi180099r17","doi-asserted-by":"crossref","DOI":"10.4135\/9781412993869","volume-title":"Fixed Effects Regression Models","author":"Allison","year":"2009"},{"key":"yoi180099r1","unstructured":"SoH-C, ChauCK, ChiuW-T, . When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disorders. bioRxiv: the Preprint Server for Biology. https:\/\/www.biorxiv.org\/content\/early\/2016\/12\/23\/096503. Posted December 23, 2016. Accessed November 15, 2018."}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamapsychiatry\/article-pdf\/76\/4\/382\/17420118\/jamapsychiatry_hayes_2019_oi_180099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T14:25:22Z","timestamp":1554301522000},"score":1,"resource":{"primary":{"URL":"http:\/\/archpsyc.jamanetwork.com\/article.aspx?doi=10.1001\/jamapsychiatry.2018.3907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.3907","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}